1.Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection.
Gut and Liver 2015;9(6):809-810
No abstract available.
Amoxicillin/*therapeutic use
;
Anti-Bacterial Agents/*therapeutic use
;
Anti-Ulcer Agents/*therapeutic use
;
Female
;
Fluoroquinolones/*therapeutic use
;
Helicobacter Infections/*drug therapy
;
Humans
;
Male
;
Metronidazole/*therapeutic use
;
Organometallic Compounds/*therapeutic use
;
Rabeprazole/*therapeutic use
;
Tetracycline/*therapeutic use
3.Clinical audit of current Helicobacter pylori treatment outcomes in Singapore.
Tiing Leong ANG ; Kim Wei LIM ; Daphne ANG ; Yu Jun WONG ; Malcolm TAN ; Andrew Siang YIH WONG
Singapore medical journal 2022;63(9):503-508
INTRODUCTION:
H. pylori eradication reduces the risk of gastric malignancies and peptic ulcer disease. First-line therapies include 14-day PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) and PBMT (PPI, bismuth, metronidazole, tetracycline). Second-line therapies include 14-day PBMT and PAL (PPI, amoxicillin, levofloxacin). This clinical audit examined current treatment outcomes in Singapore.
METHODS:
Clinical data of H. pylori-positive patientswho underwent empirical first- and second-line eradication therapies from 1 January 2017 to 31 December 2018 were reviewed. Treatment success was determined by 13C urea breath test performed at least 4 weeks after treatment and 2 weeks off PPI.
RESULTS:
A total of 963 patients (862 PAC, 36 PMC [PPI, metronidazole, clarithromycin], 18 PBMT, 13 PBAC [PAC with bismuth], 34 others) and 98 patients (62 PMBT, 15 PAL, 21 others) received first-and second-line therapies respectively. A 14-day treatment duration was appropriately prescribed for first- and second-line therapies in 65.2% and 82.7% of patients, respectively. First-line treatment success rates were noted for PAC (seven-day: 76.9%, ten-day: 88.3%, 14-day: 92.0%), PMC (seven-day: 0, ten-day: 75.0%, 14-day: 69.8%), PBMT (ten-day: 100%, 14-day: 87.5%) and PBAC (14-day: 100%). 14-day treatment was superior to seven-day treatment (90.8% vs. 71.4%; P = 0.028). PAC was superior to PMC (P < 0.001) but similar to PBMT (P = 0.518) and PBAC (P = 0.288) in 14-day therapies. 14-day second-line PAL and PBMT had similar efficacy (90.9% vs. 82.4%; P = 0.674).
CONCLUSION
First-line empirical treatment using PAC, PBMT and PBAC for 14 days had similar efficacy. Success rates for second-line PBMT and PAL were similar.
Humans
;
Helicobacter pylori
;
Clarithromycin/therapeutic use*
;
Helicobacter Infections/drug therapy*
;
Metronidazole/therapeutic use*
;
Bismuth/therapeutic use*
;
Singapore
;
Drug Therapy, Combination
;
Amoxicillin/therapeutic use*
;
Proton Pump Inhibitors/therapeutic use*
;
Anti-Bacterial Agents/therapeutic use*
;
Treatment Outcome
;
Clinical Audit
4.A Case of Esophageal Actinomycosis in a Patient with Normal Immunity.
Hyun Soo KIM ; Jong Woon CHEON ; Min Su KIM ; Chang Kil JUNG ; Kyung Rok KIM ; Jae Won CHOI ; Dong Woo KANG ; Sun Young KIM
The Korean Journal of Gastroenterology 2013;61(2):93-96
Actinomycosis is a chronic suppurative disease and caused by Actinomycosis species, principally Actinomyces israelii, which are part of the normal inhabitant on the mucous membrane of the oropharynx, gastrointestinal tract, and urogenital tract. It usually affects cervicofacial, thoracic and abdominal tissue. Cervicofacial type has the highest percentage of occurrence with 50%. Actinomycosis frequently occurs following dental extraction, jaw surgery, chronic infection or poor oral hygiene. It may also be considered as an opportunistic infection in immunocompromised patients such as malignancy, human immunodeficiency virus infection, diabetes mellitus, steroid usage or alcoholism. But, actinomycosis rarely occurs in adults with normal immunity and rare in the esophagus. We report an unusual case of esophageal actinomycosis which was developed in a patient with normal immunity and improved by therapy with intravenous penicillin G followed oral amoxicillin, and we also reviewed the associated literature.
Actinomycosis/*diagnosis/drug therapy/immunology
;
Adult
;
Amoxicillin/therapeutic use
;
Anti-Bacterial Agents/therapeutic use
;
Esophageal Diseases/*diagnosis/drug therapy/immunology
;
Esophagoscopy
;
Female
;
Humans
;
Immunity
;
Penicillin G/therapeutic use
5.New Therapeutic Strategies against Helicobacter pylori.
Bong Ku KANG ; Sung Min PARK ; Byung Wook KIM
The Korean Journal of Gastroenterology 2014;63(3):146-150
The standard therapy for Helicobacter pylori infection in Korea is a triple-drug regimen consisting of a proton pump inhibitor with two antibiotics such as clarithromycin, amoxicillin, and metronidazole. However, as the eradication rate of this regimen has declined over the past decade, this prompted the formulation of new therapeutic regimens. New therapeutic strategies against H. pylori infection that had been tried all over the world include sequential therapy, concomitant therapy, and tailored therapy This article will review the basic concepts and the results of previous clinical trials on the aforementioned new therapeutic regiments.
Amoxicillin/pharmacology/therapeutic use
;
Anti-Bacterial Agents/pharmacology/*therapeutic use
;
Clarithromycin/pharmacology/therapeutic use
;
Disease Eradication/trends
;
Drug Therapy, Combination
;
Helicobacter Infections/*drug therapy
;
*Helicobacter pylori/drug effects
;
Humans
;
Nitroimidazoles/pharmacology/therapeutic use
;
Proton Pump Inhibitors/pharmacology/therapeutic use
6.Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Shasha CHEN ; Weina SHEN ; Yuhuan LIU ; Qiang DONG ; Yongquan SHI
Chinese Medical Journal 2023;136(14):1690-1698
BACKGROUND:
With the development of traditional Chinese medicine research, berberine has shown good efficacy and safety in the eradication of Helicobacter pylori (H. pylori). The present study aimed to evaluate the efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for the initial treatment of H. pylori.
METHODS:
This study was a single-center, open-label, parallel, randomized controlled clinical trial. Patients with H. pylori infection were randomly (1:1:1) assigned to receive berberine triple therapy (berberine 500 mg, amoxicillin 1000 mg, vonoprazan 20 mg, A group), vonoprazan quadruple therapy (vonoprazan 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, colloidal bismuth tartrate 220 mg, B group), or rabeprazole quadruple therapy (rabeprazole 10 mg, amoxicillin 1000 mg, clarithromycin 500 mg, colloidal bismuth tartrate 220 mg, C group). The drugs were taken twice daily for 14 days. The main outcome was the H. pylori eradication rate. The secondary outcomes were symptom improvement rate, patient compliance, and incidence of adverse events. Furthermore, factors affecting the eradication rate of H. pylori were further analyzed.
RESULTS:
A total of 300 H. pylori-infected patients were included in this study, and 263 patients completed the study. An intention-to-treat (ITT) analysis showed that the eradication rates of H. pylori in berberine triple therapy, vonoprazan quadruple therapy, and rabeprazole quadruple therapy were 70.0% (70/100), 77.0% (77/100), and 69.0% (69/100), respectively. The per-protocol (PP) analysis showed that the eradication rates of H. pylori in these three groups were 81.4% (70/86), 86.5% (77/89), and 78.4% (69/88), respectively. Both ITT analysis and PP analysis showed that the H. pylori eradication rate did not significantly differ among the three groups (P >0.05). In addition, the symptom improvement rate, overall adverse reaction rate, and patient compliance were similar among the three groups (P >0.05).
CONCLUSIONS
The efficacy of berberine triple therapy for H. pylori initial treatment was comparable to that of vonoprazan quadruple therapy and rabeprazole quadruple therapy, and it was well tolerated. It could be used as one choice of H. pylori initial treatment.
Humans
;
Amoxicillin/therapeutic use*
;
Helicobacter pylori
;
Anti-Bacterial Agents
;
Clarithromycin/therapeutic use*
;
Rabeprazole/therapeutic use*
;
Berberine/therapeutic use*
;
Bismuth
;
Helicobacter Infections/drug therapy*
;
Drug Therapy, Combination
;
Treatment Outcome
;
Proton Pump Inhibitors/therapeutic use*
8.Meta-Analysis of First-Line Triple Therapy for Helicobacter pylori Eradication in Korea: Is It Time to Change?.
Eun Jeong GONG ; Sung Cheol YUN ; Hwoon Yong JUNG ; Hyun LIM ; Kwi Sook CHOI ; Ji Yong AHN ; Jeong Hoon LEE ; Do Hoon KIM ; Kee Don CHOI ; Ho June SONG ; Gin Hyug LEE ; Jin Ho KIM
Journal of Korean Medical Science 2014;29(5):704-713
Proton pump inhibitor (PPI)-based triple therapy consisting of PPI, amoxicillin, and clarithromycin, is the recommended first-line treatment for Helicobacter pylori infection. However, the eradication rate of triple therapy has declined over the past few decades. We analyzed the eradication rate and adverse events of triple therapy to evaluate current practices in Korea. A comprehensive literature search was performed up to August 2013 of 104 relevant studies comprising 42,124 patients. The overall eradication rate was 74.6% (95% confidence interval [CI], 72.1%-77.2%) by intention-to-treat analysis and 82.0% (95% CI, 80.8%-83.2%) by per-protocol analysis. The eradication rate decreased significantly from 1998 to 2013 (P < 0.001 for both intention-to-treat and per-protocol analyses). Adverse events were reported in 41 studies with 8,018 subjects with an overall incidence rate of 20.4% (95% CI, 19.6%-21.3%). The available data suggest that the effectiveness of standard triple therapy for H. pylori eradication has decreased to an unacceptable level. A novel therapeutic strategy is warranted to improve the effectiveness of first-line treatment for H. pylori infection in Korea.
Alkylating Agents/therapeutic use
;
Amoxicillin/therapeutic use
;
Anti-Bacterial Agents/therapeutic use
;
Anti-Ulcer Agents/therapeutic use
;
Clarithromycin/therapeutic use
;
*Communicable Disease Control
;
Cytochrome P-450 CYP3A Inhibitors/therapeutic use
;
*Disease Eradication
;
*Drug Resistance, Bacterial
;
Drug Therapy, Combination
;
Gastritis/microbiology/pathology
;
Helicobacter Infections/*drug therapy
;
Helicobacter pylori
;
Humans
;
Metronidazole/therapeutic use
;
Proton Pump Inhibitors/*therapeutic use
;
Republic of Korea
;
Tinidazole/therapeutic use
9.Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori.
Tao GUO ; Qiang WANG ; Xi WU ; Xiao Qing LI ; Yue LI ; Gui Jun FEI ; Hui Jun SHU ; Jing Nan LI ; Jia Ming QIAN
Acta Academiae Medicinae Sinicae 2019;41(1):75-79
Objective To evaluate the efficacy and safety of amoxicillin-clarithromycin-containing bismuth quadruple regimen as a primary therapy for Helicobacter pylori (Hp) eradication.Methods A total of 102 Hp-infected outpatients diagnosed by C-or C-urea breath test from December 2015 to June 2017 were enrolled and received 14-day bismuth quadruple therapy (esomeprazole 20 mg bid,bismuth potassium citrate 220 mg bid,amoxicillin 1000 mg bid,and clarithromycin 500 mg bid for 14 days). Hp status was assessed by C-or C-urea breath test 4 weeks,8 weeks,6 months,and 12 months after the treatment. The primary outcome was Hp eradication rate,which was analyzed by intention-to-treat (ITT) and per-protocol (PP) analyses. The second outcomes were Hp infection recurrence,symptomatic benefit from Hp eradication,and safety. Results A total of 101 patients,of which 65 patients had dyspeptic symptoms before eradication,completed the study. Hp eradication rates by ITT analysis and by PP analysis were 88.2% and 89.1%,respectively. Only in two of 84 patients,who were followed for 8 weeks after eradication,Hp became positive. No Hp recurrence happened at the 6-month and 12-month follow-up and the annual recurrence rate was 2.4%. The symptomatic relief rates at the 4-week,8-week,6-month and 12-month follow-up were 81.5%,75.4%,71.2%,and 70.2% respectively. Eleven of 101 patients had mild and similar side-effects,which were well tolerated.Conclusion Amoxicillin-clarithromycin-containing bismuth quadruple regimen can be used as the standard therapy for Hp eradication.
Amoxicillin
;
therapeutic use
;
Anti-Bacterial Agents
;
Bismuth
;
Clarithromycin
;
therapeutic use
;
Drug Therapy, Combination
;
Helicobacter Infections
;
drug therapy
;
Helicobacter pylori
;
Humans
;
Treatment Outcome
10.The Trend of Eradication Rates of First-line Triple Therapy for Helicobacter pylori Infection: Single Center Experience for Recent Eight Years.
You Sik CHOI ; Jae Hee CHEON ; Jong Yeul LEE ; Sang Gyun KIM ; Joo Sung KIM ; Nayoung KIM ; Dong Ho LEE ; Jung Mogg KIM ; Hyun Chae JUNG ; In Sung SONG
The Korean Journal of Gastroenterology 2006;48(3):156-161
BACKGROUND/AIMS: The prevalence of antibiotic resistance in Helicobacter pylori (H. pylori) infection has been reported to be increasing. However, the recent trend of eradication rates of H. pylori using first-line triple regimens has been rarely issued. Therefore, we aimed to determine the trend of H. pylori eradication rates in single center for recent eight years. METHODS: From January 1998 through October 2005, H. pylori eradication rates in 525 patients with H. pylori-positive peptic ulcer disease who received one-week triple regimens were retrospectively evaluated according to years, regimens, and ulcer locations. RESULTS: The overall H. pylori eradication rate was 78.7%. Yearly eradication rates from the year 1998 to 2005 were 83.7%, 80.4%, 81.4%, 78.8%, 75.3%, 77.6%, 78.9% and 77.6% consecutively by per-protocol analysis, However, no definite evidence of decreasing tendency of eradication rate was seen during the past eight years (p=0.419). Furthermore, there was no significant difference in the eradication rates according to the ulcer locations and regimens. CONCLUSIONS: Although it is found that there is no definite statistical evidence of decreasing trend for H. pylori eradication rate during past eight years, those for recent 5 years were lower than 80%, which suggests that we should scrutinize the trend of first-line H. pylori eradication rate, and concern for the expected lower rates in the near future.
Adult
;
Aged
;
Aged, 80 and over
;
Amoxicillin/therapeutic use
;
Anti-Bacterial Agents/therapeutic use
;
Clarithromycin/therapeutic use
;
Drug Therapy, Combination
;
Female
;
Helicobacter Infections/*drug therapy
;
*Helicobacter pylori
;
Humans
;
Male
;
Metronidazole/therapeutic use
;
Middle Aged
;
Retrospective Studies
;
Treatment Outcome